This article is for information only and does not constitute legal advice issued by an attorney. If you need legal advice, please contact Veritas Law at: erica.wang@thevertiaslaw.com
In recent years, the life science industry has experienced a significant uptick in cross-border collaboration deals, particularly between multinational pharmaceutical companies and emerging biotech firms, especially biotech firms from China. These partnerships serve distinct but complementary purposes for the parties involved.
For Global Pharma: Access to Innovation and Speed. Pharma companies, often burdened with high R&D costs and long development timelines, are increasingly turning to external innovation to supplement their pipelines. Collaborating with nimble, research-intensive biotech firms allows them to access novel therapeutic modalities—such as bispecific antibodies, antibody-drug conjugates (ADCs), and cell therapies—that are often developed more rapidly and cost-effectively by smaller players.
Pfizer’s 2025 licensing deal with China’s 3SBio for the bispecific antibody SSGJ-707 exemplifies this trend. The deal, which included $1.25 billion upfront and up to $4.8 billion in milestone payments, underscores the growing global recognition of Chinese innovation. It also highlights how such collaborations can serve as a bridge between scientific discovery and global commercialization.
For Chinese Biotech: Monetization, Validation, and Global Reach. Chinese biotech firms, on the other hand, benefit from these partnerships by gaining access to funding, global validation, and commercialization pathways outside of China. Amid tightening IPO markets and limited access to private equity, these deals provide a lifeline for continued innovation and growth. Partnerships with big pharma also serve as endorsements of scientific credibility and clinical potential, leveraging the global development experience of their partners and offering the potential to share in future commercial upside.
The Strategic Importance of IP in Cross-Border Collaborations
As cross-border collaborations become more prevalent, the importance of intellectual property (IP) as a foundational element of these partnerships cannot be overstated. These partnerships often involve highly valuable assets—ranging from novel biologics to proprietary platforms—and the success of such collaboration hinges on how well IP rights are defined, protected, and respected.
In the context of drug R&D, IP typically includes patents, proprietary technologies, and clinical data, among others. To ensure mutual trust and long-term value creation, collaboration agreements must (1) clearly delineate background IP brought into the partnership by each party, (2) define ownership and usage rights for any jointly developed IP or improvements, and (3) establish robust mechanisms for confidentiality, licensing, and dispute resolution.
For both pharma licensees and biotech licensors, well-structured IP frameworks are essential: not only for safeguarding innovation, but also for enabling regulatory clarity, future deal-making, and ultimate, successful commercialization.
Background vs. Foreground IP
A critical aspect of structuring collaboration agreements is distinguishing between background IP and foreground IP. This distinction lays the groundwork for determining ownership, usage rights, and the scope of the collaboration.
Background IP refers to the intellectual property that each party brings into the collaboration. This may include existing patents, proprietary platforms, and technical know-how. It is essential that background IP is clearly identified and documented at the outset of the collaboration to prevent any ambiguity or unintended transfer of rights.
Foreground IP, on the other hand, encompasses any new inventions, data, or technologies developed during the course of the collaboration. This includes jointly developed compounds, clinical trial data, and new methods or processes. The ownership and usage rights of foreground IP must be explicitly defined in the collaboration agreement.
Proper delineation of background and foreground IP ensures that each party retains control over its pre-existing assets while providing a clear framework for managing jointly developed innovations.
Defining and Navigating Collaboration IP
Building on the distinction between background and foreground IP, collaboration IP refers specifically to the intellectual property that is jointly created during the course of a partnership. This may include data, know-how, or patentable inventions developed by either party, or their affiliates, subcontractors, or third-party collaborators, while performing activities under the collaboration agreement.
Crucially, collaboration IP excludes any background IP brought into the partnership, as well as any IP developed independently and outside the scope of the joint effort.
As cross-border R&D partnerships evolve, each party contributes unique assets, such as proprietary platforms, scientific expertise, or clinical infrastructure, toward shared innovation goals. While this synergy can accelerate development, it also introduces complex questions around ownership, usage rights, and commercialization of the resulting IP.
For instance, if a new therapeutic compound is developed jointly, who owns the patent? Can either party license it independently? What happens if one party wants to pursue a different indication or market?
To ensure mutual benefit and minimize future disputes, collaboration agreements must clearly define:
- Ownership structures (e.g., sole vs. joint ownership),
- Licensing rights and sublicensing conditions,
- Commercialization responsibilities and revenue sharing, and
- Dispute resolution mechanisms.
Types of Collaboration IP: Sole vs. Joint
Collaboration IP can be further classified based on the nature of the inventive contribution:
Sole Collaboration IP arises when one party independently invents or develops IP during the collaboration. In such cases, that party retains exclusive ownership, while the other party may receive a limited license to use the IP for specific purposes (e.g., research or commercialization within a defined field).
Joint Collaboration IP is created when both parties contribute to the conception and development of the invention. This typically occurs in integrated R&D efforts where both parties share technical expertise, data, and resources.
The choice between sole and joint ownership should be guided by the nature of the collaboration, the contributions of each party, and the intended use of the resulting IP. In many cases, assigning ownership to one party with a well-defined license to the other may offer a more practical and efficient solution.
Legal Complexities of Joint Ownership
Joint ownership of IP, particularly patents, presents legal complexities that vary by jurisdiction. These differences can have significant implications for how IP is used, licensed, and enforced.
In the United States, each joint owner of a patent can use or license the patent without the consent of the other owners. However, exclusive licenses require unanimous agreement, and enforcement actions must include all co-owners as plaintiffs.
In Japan and the United Kingdom, licensing typically requires the consent of all co-owners, although use without consent is generally permitted.
To navigate these complexities, collaboration agreements should include provisions that: (1) designate a lead party for patent prosecution and enforcement, (2) establish procedures for granting licenses, and (3) define mechanisms for resolving disputes.
Best Practices for Structuring Collaboration IP
To ensure the success of a collaboration and the effective management of IP, parties should adopt a set of best practices:
• Clearly define inventorship and ownership at the outset of the collaboration. Use detailed contractual language to avoid ambiguity,
• Where possible, avoid joint ownership. Instead, assign ownership to one party and grant the other a license tailored to its needs,
• Establish governance mechanisms, such as joint steering committees or IP management boards, to oversee the development and use of collaboration IP, and
• Include robust dispute resolution clauses, specifying arbitration procedures, governing law, and jurisdiction.
Supporting IP Provisions in Collaboration Agreements
Beyond defining ownership and licensing of background and foreground IP, collaboration agreements should also include supporting IP provisions that ensure operational clarity, risk management, and long-term alignment between partners. These provisions may include:
• Patent management and cost sharing. Designate responsibility for filing, prosecuting, and maintaining patents, and outline how costs will be shared,
• Third-party claims. Define procedures for handling infringement claims and enforcement actions, and
• Confidentiality and publication rights. Protect sensitive information and regulate public disclosures to prevent unintended IP loss.
These operational provisions are essential for ensuring that the collaboration functions smoothly and that both parties are protected throughout the lifecycle of the partnership.
The Rise of NewCos: A New Model for Collaboration
An emerging trend in the biotech industry is the formation of NewCos: new companies established around in-licensed assets, as seen from multiple Chinese biotech firms. These entities serve as vehicles for advancing specific assets through development and commercialization.
The NewCos model represents a hybrid approach to collaboration—combining licensing, investment, and strategic execution. The success of NewCos depends heavily on the clarity and enforceability of their IP rights. As such, robust IP and collaboration frameworks are essential to their viability and long-term value creation.
Conclusion: IP as the Engine of Cross-Border Collaboration and Innovation
In today’s interconnected drug R&D landscape, collaboration is not just a strategic option, it is a necessity. But collaboration without clarity is a recipe for conflict. Intellectual property is the engine that powers innovation, and its structure determines the trajectory of a partnership.
By thoughtfully defining ownership, licensing, governance, and enforcement mechanisms, companies can unlock the full potential of cross-border collaborations. Whether through traditional licensing, co-development, or the formation of NewCos, the future of drug development will be shaped by those who master the art and science of collaboration IP.
In a world where scientific discovery transcends borders, the ability to collaborate effectively—and to protect what is created together—will define the next generation of medical breakthroughs.